Trial
NCT04539366
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Recurrent Childhood Neuroblastoma
Intervention
Biopsy Procedure
Why stopped
Other - review of safety data
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-13